| 臺大學術典藏 |
2021-03-09T05:18:37Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:36Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:33Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:29Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-02-23T08:26:15Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H.;Shao Y.-Y.;Lin C.-C.;Sung-Hsin Kuo;Cheng A.-L.;Yeh K.-H.; Yang S.-H.; Shao Y.-Y.; Lin C.-C.; SUNG-HSIN KUO; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
Solving the deficit of cancer pain management skills by education programs
|
Shao Y.-Y.;Lin W.-Y.;Lin C.-P.;Lu L.-C.;Chih-Hung Hsu; Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; Lu L.-C.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Shao Y.-Y.;Hsu C.;Chih-Hung Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
|
Liu T.-H.;Shao Y.-Y.;Chih-Hung Hsu; Liu T.-H.; Shao Y.-Y.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma
|
Wu C.-H.;Liang P.-C.;Chih-Hung Hsu;Chang F.-T.;Shao Y.-Y.;Ting-Fang Shih T.; Wu C.-H.; Liang P.-C.; CHIH-HUNG HSU; Chang F.-T.; Shao Y.-Y.; Ting-Fang Shih T. |
| 臺大學術典藏 |
2021-02-18T08:01:12Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Chiun Hsu;Cheng A.-L.; Lu L.-C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Chiun Hsu;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.; Shao Y.-Y.; Liu T.-H.; Chiun Hsu; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Chiun Hsu;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Chiun Hsu; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Shao Y.-Y.;Chiun Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Chiun Hsu; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:21Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chiun Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Chiun Hsu; Cheng A.-L.; Lee R.-C.; Chao Y. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:34Z |
Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer
|
Chen K.-H.;Shao Y.-Y.;Lin Z.-Z.;Yeh Y.-C.;Wen-Yi S.;Kuo R.N.;Chen H.-M.;Lai C.-L.;Kun-Huei Yeh;Cheng A.-L.;Lai M.-S.; Chen K.-H.; Shao Y.-Y.; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; KUN-HUEI YEH; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-01-28T01:06:30Z |
Young patients with colorectal cancer have increased risk of second primary cancers
|
Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; KUN-HUEI YEH; Lai M.-S. |
| 臺大學術典藏 |
2021-01-28T01:06:29Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Shao Y.-Y.; Hsu C.-H.; KUN-HUEI YEH; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-01-28T01:06:27Z |
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study
|
Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:25Z |
Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study
|
Liang Y.-H.;Shao Y.-Y.;Chen H.-M.;Cheng A.-L.;Lai M.-S.;Kun-Huei Yeh; Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Cheng A.-L.; Lai M.-S.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:23Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Liang Y.-H.;Wei C.-H.;Hsu W.-H.;Shao Y.-Y.;Lin Y.-C.;Chou P.-C.;Cheng A.-L.;Kun-Huei Yeh; Liang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:19Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H.;Shao Y.-Y.;Lin C.-C.;Kuo S.-H.;Cheng A.-L.;Kun-Huei Yeh; Yang S.-H.; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021 |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2020-11-27T03:25:51Z |
National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients
|
Shao Y.-Y.;Hsiue E.H.-C.;Hsu C.-H.;Chien-An Yao;Chen H.-M.;Lai M.-S.;Cheng A.-L.; Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; CHIEN-AN YAO; Chen H.-M.; Lai M.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-11-27T03:24:52Z |
Emergency department presentation of chronic peritoneal dialysis patients
|
Pai M.-F.; Hsu S.-P.; Peng Y.-S.; Chiang C.-K.; Ho T.-I.; Shao Y.Y.; Lee H.-Y.; KUAN-YU HUNG |
| 臺大學術典藏 |
2020-10-07T08:50:38Z |
Solving the deficit of cancer pain management skills by education programs
|
WEN-YING LIN; Shao Y.-Y; Lin C.-P; Lu L.-C; Hsu C.-H. |
| 臺大學術典藏 |
2020-08-14T03:15:30Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; I-LUN SHIH; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-08-12T02:42:37Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Chao Y.; Hsu C.; Lee R.-C.; Lin Z.-Z.; BANG-BIN CHEN; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lin Z.-Z.;Bang-Bin Chen;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C. |
| 臺大學術典藏 |
2020-08-11T08:36:55Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Cheng A.-L.; Tien Y.-W.; PO-CHIN LIANG; Shao Y.-Y.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-11T08:36:51Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-07T02:32:18Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao Y.-Y.; CHIH-HORNG WU; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y;Lin C.C;Chih-Hsin Yang; Shao Y.Y; Lin C.C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions
|
Shao Y.-Y;Hu F.-C;Liang J.-T;Chiu W.-T;Cheng A.-L;Chih-Hsin Yang; Shao Y.-Y; Hu F.-C; Liang J.-T; Chiu W.-T; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:08Z |
Survival of patients with small cell lung carcinoma in Taiwan
|
Lai M.-S.;Chih-Hsin Yang;Kuo R.N.C;Shau W.-Y;Shao Y.-Y;Yang Y.-Y;Lin Z.-Z;Kuo Y.-H; Kuo Y.-H; Lin Z.-Z; Yang Y.-Y; Shao Y.-Y; Shau W.-Y; Kuo R.N.C; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:06Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Chengb A.-L.;Hsu C.-H;Hong R.-L;Chih-Hsin Yang;Chang D.-Y;Shao Y.-Y;Hu F.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Hu F.-C; Shao Y.-Y; Chang D.-Y; CHIH-HSIN YANG; Hong R.-L; Hsu C.-H; Chengb A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:05Z |
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study
|
Laie M.-S.;Chih-Hsin Yang;Kuo R.N.-C;Yang Y.-Y;Shao Y.-Y;Shau W.-Y;Lin Z.-Z; Lin Z.-Z; Shau W.-Y; Shao Y.-Y; Yang Y.-Y; Kuo R.N.-C; CHIH-HSIN YANG; Laie M.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:04Z |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
Shao Y.-Y;Shau W.-Y;Lin Z.-Z;Chen H.-M;Kuo R;Chih-Hsin Yang;Lai M.-S.; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; Chen H.-M; Kuo R; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z;Shau W.-Y;Hsu C;Shao Y.-Y;Yeh Y.-C;Kuo R.N.-C;Hsu C.-H;Chih-Hsin Yang;Cheng A.-L;Lai M.-S.; Lin Z.-Z; Shau W.-Y; Hsu C; Shao Y.-Y; Yeh Y.-C; Kuo R.N.-C; Hsu C.-H; CHIH-HSIN YANG; Cheng A.-L; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:56Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Chen K.-H;Lai C.-L;Kuo R.N;Lin Z.-Z;Shau W.-Y;Chen H.-M;Shao Y.-Y;Liao B.-C; Liao B.-C; Shao Y.-Y; Chen H.-M; Shau W.-Y; Lin Z.-Z; Kuo R.N; Lai C.-L; Chen K.-H; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:52Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Cheng W.-F;Hsu C;Shao Y.-Y;Yang Y.-Y;Lai C.-L;Shau W.-Y;Kuo R;Lin Z.-Z;Kuo H.-Y; Kuo H.-Y; Lin Z.-Z; Kuo R; Shau W.-Y; Lai C.-L; Yang Y.-Y; Shao Y.-Y; Hsu C; Cheng W.-F; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Lai M.-S.;Cheng A.-L;Chiang C.-J;Chen H.-M;Chih-Hsin Yang;Lee H.-S;Liao B.-C;Shao Y.-Y;Liang Y.-H; Liang Y.-H; Shao Y.-Y; Liao B.-C; Lee H.-S; CHIH-HSIN YANG; Chen H.-M; Chiang C.-J; Cheng A.-L; Lai M.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y; Chia-Chi Lin; Yang C.H. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H; Shao Y.-Y; Chia-Chi Lin; Kuo S.-H; Cheng A.-L; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-25T06:52:03Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H; Chang K.-J; Kuo W.-H; Hsu C; Lee W.-C; Liau J.-Y; Huang C.-S; Shao Y.-Y;Kuo K.-T;Hu F.-C;Yen-Shen Lu;Huang C.-S;Liau J.-Y;Lee W.-C;Hsu C;Kuo W.-H;Chang K.-J;Lin C.-H;Cheng A.-L.; Shao Y.-Y; Kuo K.-T; Hu F.-C; YEN-SHEN LU |
| 臺大學術典藏 |
2020-05-25T06:51:58Z |
The impact of diabetes mellitus on prognosis of early breast cancer in Asia
|
Lai M.-S.;Cheng A.-L;Kuo R.N.C;Chen H.-M;Yen-Shen Lu;Lin Z.-Z;Shau W.-Y;Shao Y.-Y;Chen W.-W; Chen W.-W; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; YEN-SHEN LU; Chen H.-M; Kuo R.N.C; Cheng A.-L; Lai M.-S. |
